Skip to main content

HIV PrEP Medication Costs US More Than $2 Billion Annually

Payments for HIV preexposure prophylaxis (PrEP) drugs in the United States totaled more than $2.08 billion in 2018, according to a study published online in the Annals of Internal Medicine.

Researchers investigated prescriptions for tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) for PrEP between 2014 and 2018 using the IQVIA Longitudinal Prescriptions database, which covers more than 90% of retail pharmacy prescriptions. 

Between 2014 and 2018, they found, annual PrEP prescriptions increased from 73,739 to 1.1 million. For 30 tablets, the average total payment increased from $1350 in 2014 to $1638 in 2018; the average out-of-pocket payment grew from $54 to $94. 

Out-of-pocket payments accounted for 5.7% of the $1638 cost in 2018, while third-party payments accounted for 94.3%. For 30 tablets, people with Medicaid paid an average $3. People with Medicare paid an average $80 for 30 tablets, and people with commercial insurance paid an average $107.  

Of the $2.08 billion in total payments for PrEP medication in 2018, $1.68 billion, or 80.7%, stemmed from prescriptions for people with commercial insurance, $200 million for people with Medicaid, $48 million for people with Medicare, and $127 million for people with manufacturer assistance. 

Researchers noted the IQVIA database does not include every prescription, which they considered a limitation of the study. 

“The $2.08 billion in PrEP medication payments in 2018 is an underestimation of national costs,” they wrote. “High costs to the health care system may hinder PrEP expansion.”  —Jolynn Tumolo 

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
3 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top